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Background
The human monoclonal antibody 2G12 has shown a
broadly neutralizing activity in vitro and has contributed
to protection towards virus challenge in animal models. It
binds to a carbohydrate-dependent epitope. Three major
N-linked glycosylation sites (PNGs) for 2G12 binding
(N295, N332 and N392) were identified by site directed
mutagenesis of prototype strains. We analyzed the sensi-
tivity to 2G12 of pseudoviruses carrying envelope proteins
issued from HIV-1 clade B infected patients and analyzed
the data according to the corresponding env sequences.
Methods
We studied four long-term non-progressors infected by
HIV-1 subtype B variants. Two of them developed broadly
neutralizing antibodies, defined as the capability to neu-
tralize four primary isolates of various clades. Starting
from 27 env clones, twelve functional HIV-1 pseudovi-
ruses were generated by co-transfection of 293T cells with
a plasmid expressing the relevant env gene and the
pNL4.3Δenv plasmid carrying the luciferase gene reporter.
Sensitivity to 2G12 was analyzed in TZM-bl cells.
Results
The 3 PNGs known to be essential for 2G12 binding were
present in the 3 most sensitive pseudoviruses, derived
from a single patient. At least one of these major sites was
absent in 8 of 9 clones that were resistant to neutralization
by 2G12. However one clone, although harboring the 3
PNGs, was not neutralized by 2G12. Its sequence analysis
revealed a long and heavily glycosylated V1/V2 loop (86
amino-acids and 9 PNGs) and an additional PNG at posi-
tion 302 on V3 loop.
Conclusion
Our study confirms, on naturally occurring functional env
genes, the essential role of the PNGs N295, N332 and
N392 for 2G12 binding, but also suggests that an
extended V1–V2 loop or additional PNGs on V1–V2 and
V3 loops might limit the accessibility of the 2G12 epitope.
This biological material should be useful to better charac-
terize the 2G12 epitope and analyze its role in virus entry.
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